entertainment -WSS

entertainment

author：focus 2025-09-07 17:29:33 - browse：7116

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

hotspot

WSS

Hospitals are piloting generative AI tools as regulators play catch

FDA warns medical device makers about rise in fabricated data

Affirmative action in medical school literally saved lives

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

After affirmative action ruling, medical educators look to 'holistic review'

Medicare proposal to cover medical devices draws a mixed reaction

explore

entertainment

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Elevance, SCAN deals highlight health insurer acquisition scrutiny

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Measles policy set amid Florida outbreak alarms vaccine proponents

Psychedelics group wrestles with new pharma identity

Jerome Adams on the need for new antivirals for Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

In age of alternative facts, a scholarly course on calling out crap

Hospitals are piloting generative AI tools as regulators play catch

Wikipedia

Abridge raises $150m as clinical notes automation market heats up

What does generative AI mean for health care? We asked experts

Abridge raises $150m as clinical notes automation market heats up

Supreme Court strikes down use of affirmative action

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA warns medical device makers about rise in fabricated data

focus

entertainment

hotspot

hotspot